# A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

> **NCT02987114** · PHASE2 · COMPLETED · sponsor: **PhytoTech Therapeutics, Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Epilepsy Intractable

## Interventions

- **DRUG:** PLT101

## Key facts

- **NCT ID:** NCT02987114
- **Lead sponsor:** PhytoTech Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-13
- **Primary completion:** 2018-06-28
- **Final completion:** 2018-06-28
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987114, "A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02987114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*